Compare BridgeBio Pharma Inc (BBIO) vs Skyworks Solutions Inc (SWKS) Price & Performance

BridgeBio Pharma (BBIO) trades at $83.64, down 1.22% on the day, with a bullish technical signal from moving averages and strong analyst support. Revenue surged to $502.08M in 2025, though net losses widened to -$724.93M, reflecting high R&D spending. Recent news highlights Q2 2026 earnings misses but revenue beats, driven by Attruby sales growth and three late-stage regulatory submissions expected by mid-2027.

Outlook remains optimistic with an 88% buy rating and $104.56 price target, but risks include persistent cash burn, high debt of $1.72B, and negative equity. Key catalysts are FDA decisions in 2027, with success potentially driving significant upside, though failure could exacerbate financial strain.

Skyworks Solutions (SWKS) trades at $68.17, down 0.9% today, with a bullish technical signal from moving averages and recent earnings beats in Q2 2026. The stock shows strong institutional buying interest and a 58% analyst buy rating, though revenue has declined from $5.5B in 2022 to $4.1B in 2025. The pending Qorvo combination and AI data center growth present strategic opportunities, but profitability margins have compressed, and a legal investigation adds near-term uncertainty.

The outlook is cautiously optimistic, supported by earnings consistency and diversification into automotive and AI markets, but investors face risks from integration execution, margin pressure, and regulatory scrutiny. The consensus price target of $66 suggests limited upside, requiring careful monitoring of merger progress and quarterly performance against expectations.